Navigation Links
Genaera Corporation Announces Second Quarter Financial Results
Date:8/11/2008

cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

GENAERA CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenues $ 45 $ 2,403 $ 1,354 $ 2,610

Costs and expenses:

Research and development 3,549 3,089 7,387 6,559

General and administrative 1,378 1,639 3,563 3,071

4,927 4,728 10,950 9,630

Loss from operations (4,882) (2,325) (9,596) (7,020)

Interest income 104 338 280 705

Loss before income taxes (4,778) (1,987) (9,316) (6,315)

Income tax benefit -- -- 281 147

Net loss $(4,778) $(1,987) $(9,035) $(6,168)

Net loss per share --

basic and diluted $(0.27) $(0.11) $(0.52) $(0.35)

Weighted average shares

outstanding -- basic and

diluted 17,465 17,449 17,464 17,446

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands)

June
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 According to a ... Research "Regenerative Medicine (Bone and Joint) Market (By ... Engineering; By Applications - Bone Graft Substitutes, Osteoarticular ... Global Industry Analysis, Size, Share, Growth, Trends and ... (bone and joint) market was valued at USD ...
(Date:7/28/2014)... /PRNewswire/ -   JOLT , a leading technology accelerator, ... its growing portfolio of startups. Next-level tech and boundary-pushing ... JOLT accelerator, and Cohort four is no exception, ... Since its launch in July 2012, JOLT has ... financing. Now at 23 investments, JOLT,s portfolio has an ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)... It’s a hard truth: Nearly half of recent veterans who ... are failing to obtain a diploma or certificate within a ... an analysis by The Resume Place , a major ... college majors, which leads to underemployment, unemployment or just plain ... of post-9/11 veterans using GI Bill education benefits ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4
... TRIANGLE PARK, N.C., Jan. 24 Quintiles,Transnational Corp. ... investor partnership to support the company,s continued,growth under ... CEO Dennis,Gillings, CBE, and the management team. Gillings ... Capital have become the lead,investors in Quintiles, with ...
... BOHEMIA, N.Y., Jan. 23 NBTY, Inc. (NYSE: NTY ... nutritional,supplements, today announced it will web cast a conference call ... http://www.nbty.com on,Monday, January 28, 2008 at 8:30 AM ... will be issued at 7:00 AM (ET) that,day., A ...
... PPD, Inc. (Nasdaq:,PPDI) today announced that it ... through an exclusive agreement with Peking Union Lawke,Biomedical ... begin,immediately providing biopharmaceutical clients with its full range ... "Chinese law makes it extremely difficult to export ...
Cached Biology Technology:Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 2Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i 3NBTY to Web Cast Fiscal First Quarter Conference Call 2PPD Expands Global Central Lab Services into China 2PPD Expands Global Central Lab Services into China 3
(Date:7/27/2014)... N.C. -- Microorganisms like bacteria and fungi can evade ... antibiotics or antifungal drugs. These permanent mutations were once ... to evolve. Now a new study has shown that ... -- known as epimutations -- to gain the benefits ... new mechanism was discovered in a fungus called Mucor ...
(Date:7/27/2014)... Institute have found that targeting a molecule in blood ... to research published in Nature today (Sunday)., ... Mary University of London, have found that a molecule, ... repair itself after chemotherapy or radiotherapy, which kill cancer ... from blood vessels that grew in melanoma or lung ...
(Date:7/27/2014)... 18,000 patients, scientists have identified more than two ... including six that had not been previously reported. ... was partially funded by the National Institutes of ... NIH laboratories. , "Unraveling the genetic underpinnings of ... involved in this complex disease, and hopefully, may ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
... , Construction of ENJOY: A Generation House, the U.S. Department ... a collaborative effort of Rutgers, The State University of New ... following a recent ground-breaking at NJIT. Once construction of ... topping-off event at NJIT with major sponsors and VIP guests. ...
... (Boston) Kenneth Walsh, PhD, FAHA, the Aram ... of the Whitaker Cardiovascular Institute at Boston University ... 2011 American Heart Association (AHA) Distinguished Scientist. The ... The AHA created a Distinguished Scientist designation ...
... University biologists identified a new way in which bacteria hijack ... new antibiotics. Zhao-Qing Luo, the associate professor of biological ... new enzyme used by the bacterium Legionella pneumophila ... cell in order to take up residence. "Legionnaires, disease ...
Cached Biology News:Team New Jersey to make precast concrete solar house reality 2BUSM professor selected as American Heart Association Distinguished Scientist 2Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
... ( Abpromise for all tested ... Synthetic peptide: DWLCL AFVE SKFNISKINE NADGSFDYGL ... amino acids 46-100 of Human LYZL6 ... 57151 Swiss ...
Biology Products: